OncoMatch/Clinical Trials/NCT05387603
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
Is NCT05387603 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including 177Lu-DOTATOC and Capecitabine for neuroendocrine tumors.
Treatment: 177Lu-DOTATOC · Capecitabine — There are several ways of personalizing PRRT (peptide receptor radionuclide treatment) in NEN (neuroendocrine neoplasia). Nevertheless, the current treatment regimen is not personalized. This trial aims to compare personalized PRRT to non-personalized PRRT in terms of safety, efficacy and resource demands in order to optimize treatment outcomes in an evidence-based manner in future.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Radioligand therapy
Cancer type
Neuroendocrine Tumor
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: peptide receptor radionuclide therapy
Lab requirements
Blood counts
Hemoglobin > 90 g/L, platelets >100 x10^9/L, leukocytes > 3.0x10^9/L, neutrophils > 1.5 x10^9/L
Kidney function
GFR > 50 ml/min/1.73 m2 as determined by iohexol- or 51Cr-EDTA clearance, calculated according to a combination of LMR18 and CAPA formulas, or equally accurate method
Liver function
ASAT/ALAT < 3 x ULN, bilirubin < 2 x ULN, albumin > 25 g/L
Hemoglobin > 90 g/L, platelets >100 x109/L, leukocytes > 3.0x109/L, neutrophils > 1.5 x109/L, aspartate transaminase (ASAT)/alanine aminotransferase (ALAT) < 3 x ULN, bilirubin < 2 x upper limit of normal (ULN), albumin > 25 g/L. GFR > 50 ml/min/1.73 m2 as determined by iohexol- or 51Cr-EDTA clearance, calculated according to a combination of LMR18 and CAPA formulas, or equally accurate method
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05387603 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior peptide receptor radionuclide therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages